ArticleCureus2025
Rituximab-Based Management of Autoimmune Blistering Diseases: A Case Series Highlighting Ocular and Systemic Presentations.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucous membrane pemphigoid (MMP), bullous pemphigoid (BP), and pemphigus vulgaris (PV) are rare autoimmune blistering disorders of the skin and mucous membranes that often result in delayed diagnosis and substantial morbidity. MMP is characterized by progressive conjunctival scarring, while BP typically presents with tense cutaneous blisters and PV with intraepidermal acantholysis driven by desmoglein autoantibodies. We present two women, aged 68 and 89 years, with ocular MMP, and one woman with PV, aged 48 years, highlighting the importance of early ophthalmic evaluation and prompt immunosuppressive therapy. Histopathology and immunofluorescence confirmed disease-specific patterns, with MMP demonstrating conjunctival fibrosis and subepithelial blistering, and PV showing vesiculobullous eruptions and antibody-mediated activity. All three patients responded favorably to rituximab, achieving steroid-sparing remission and stable disease control, underscoring its role as a key therapeutic option, particularly in vision-threatening ocular MMP. These findings emphasize the need for timely biopsy, comprehensive antibody testing, and early intervention, while supporting further research to standardize rituximab regimens and optimize long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.